Abcam, ab255757, Anti-CYP46A1 antibody [1A7] - BSA and Azide free

Size: 100µg / 1mg
Mouse Recombinant Monoclonal CYP46A1 antibody. Carrier free. Suitable for WB, IHC-P and reacts with Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:1A7,
Isotype:IgG1,
Carrier free:Yes,
Reacts with:Mouse, Rat,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab255757 is the carrier-free version of
ab244241
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CYP46A1 also known as cholesterol 24-hydroxylase is a member of the cytochrome P450 superfamily. It has a molecular mass of approximately 56 kDa. CYP46A1 is expressed mainly in the brain specifically within neurons that are active in cholesterol metabolism. This enzyme localizes in the endoplasmic reticulum and is responsible for converting cholesterol into 24S-hydroxycholesterol a more soluble form that can cross the blood-brain barrier.
Biological function summary
The conversion of cholesterol to 24S-hydroxycholesterol by CYP46A1 helps maintain cholesterol homeostasis in the central nervous system. This process is not part of a large complex but it plays an important role in the clearance of excess cholesterol from the brain. The removal of cholesterol metabolites is essential for normal brain function and neuronal health.
Pathways
CYP46A1's activity fits into the cholesterol catabolism pathway to regulate cholesterol levels specifically in the brain. The enzyme interacts with pathways that include cholesterol turnover and removal from the central nervous system. In this context CYP46A1 is related to APOE a protein involved in lipid metabolism and transport contributing to the balance of cholesterol and lipids in the brain.
Alterations in CYP46A1 have associations with Alzheimer’s disease and Huntington’s disease. In Alzheimer’s disease abnormal cholesterol metabolism involving CYP46A1 may result in the formation of amyloid plaques as the enzyme is linked to APP which is important in the pathology of Alzheimer's. In Huntington’s disease disruption of cholesterol homeostasis by dysregulation of CYP46A1 might aggravate neuronal degeneration suggesting a potential therapeutic target for neuroprotection.